R&D Trends

Pfizer signs precision medicine research agreement with Medco

Thursday, October 27, 2011 01:41 PM

Pfizer has established a research collaboration with Medco Health Solutions and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes.

More... »

Life Technologies, GSK ink cancer research agreement

Wednesday, October 26, 2011 10:55 AM

Life Technologies has signed an agreement with GlaxoSmithKline to develop a diagnostic to be used as a companion test with a GSK candidate cancer immunotherapy. Life will develop a qPCR-based molecular diagnostic assay for GSK's MAGE-A3 cancer immunotherapy candidate designed to identify patients likely to benefit from the immunotherapy.

More... »

Immune Design, Sanofi collaborate in allergy research

Wednesday, October 26, 2011 10:39 AM

Immune Design has entered into an early-stage research collaboration with Sanofi-Aventis to investigate the use of IDC's Glucopyranosyl Lipid Adjuvant (GLA) technology, a toll–like receptor 4 (TLR-4) agonist, in the field of allergy.

More... »

VTT, MSI open Center for Bioengineering in California

Wednesday, October 26, 2011 10:14 AM

The VTT Technical Research Centre of Finland and the Molecular Sciences Institute (MSI) have joined forces to establish a new research center in Berkeley, California.

More... »

Foundation Medicine, Johnson & Johnson collaborate in oncology research

Tuesday, October 25, 2011 01:10 PM

Foundation Medicine has reported a collaboration with Johnson & Johnson Pharmaceutical Research and Development. The collaboration is focused on using Foundation Medicine's comprehensive clinical cancer genomic test to identify potential biomarkers to support J&JPRD oncology clinical development programs. Financial details of the agreement were not disclosed.

More... »

ProBioGen, Inhibrx ink license agreement

Tuesday, October 25, 2011 12:02 PM

ProBioGen and Inhibrx signed a multi-program license deal on ADCC-enhanced therapeutic antibodies. ProBioGen’s GlymaxX ADCC enhancement technology and mammalian cell line development and manufacturing services will be used to advance therapeutic antibodies generated by Inhibrx’s discovery platforms.

More... »

Gilead, GlobeImmune collaborate

Tuesday, October 25, 2011 11:46 AM

Gilead Sciences and GlobeImmune have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of therapeutic vaccine products for use in conjunction with Viread (tenofovir disoproxil fumarate) and other oral therapies for the treatment of chronic hepatitis B virus (HBV) infection.

More... »

Parkinson’s Disease Foundation adds 27 research adovcates

Thursday, October 20, 2011 02:43 PM

The Parkinson's Disease Foundation welcomes 27 new members to its national network of research advocates who are influencing research and speeding the development of new and effective treatments for Parkinson's.  This week in New Jersey, the members from the Northeast region are completing an intensive three-day training to prepare them to join the network, known as Parkinson's Advocates in research.

More... »

Venture capital investments in life sciences fall in third quarter

Wednesday, October 19, 2011 01:07 PM

Venture capitalists invested $6.95 billion in 876 deals in the third quarter of 2011, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters.

More... »

IDRI joins ADITEC to accelerate human vaccine development

Tuesday, October 18, 2011 02:19 PM

The Infectious Disease Research Institute (IDRI) has joined the Advanced Immunization Technologies (ADITEC) program, a collaborative initiative dedicated to accelerating the development of the next generation of human vaccines. Launched on October 1st, ADITEC will operate with 30 million euros in funding over the course of 5 years contributed by the European Union, with an additional 11 million euros in funding from collaborating organizations.

More... »